Cas9 Stable Cell Line - ARPE-19

The Cas9 Stable Cell Line—ARPE-19—is a genetically engineered human retinal pigment epithelium cell line derived from the parental ARPE-19 cells, which were originally isolated from the retina of an adult human donor. This cell line has been modified to stably express the CRISPR-associated protein 9 (Cas9) endonuclease—a key component of the CRISPR-Cas9 genome editing system. The stable integration of the Cas9 gene ensures continuous and long-term expression of the enzyme, thereby eliminating the need for repetitive transfection procedures. ARPE-19 cells are highly valued for their distinct epithelial morphology, their capacity for polarization, and their functional characteristics, which closely mimic those of native retinal pigment epithelium (RPE) cells.

Researchers can utilize this cell line to perform targeted gene knockouts, knock-ins, or transcriptional activation within retinal disease models, thereby gaining deeper insights into the pathogenesis of conditions such as Age-Related Macular Degeneration (AMD), Retinitis Pigmentosa, and Diabetic Retinopathy. The stable expression of Cas9 significantly streamlines high-throughput CRISPR screening workflows, enabling researchers to systematically identify key genes involved in RPE function, oxidative stress responses, and angiogenesis. Furthermore, this cell line accelerates the drug discovery and development process by facilitating the rapid validation of therapeutic targets within a physiologically relevant cellular system. Its excellent compatibility with cutting-edge technologies—such as live-cell imaging, electrophysiology, and co-culture systems—further facilitates in-depth investigations into intercellular interactions, barrier function, and drug delivery mechanisms.